Dipeptidyl-Peptidase 4 (Cd26): a Possible Therapeutic Target in Covid-19

Volume 2 - Issue 1

Galimberti S¹*, Morabito F^2,3, Gentile M⁴, Baratè C⁵, Benedetti E⁵, Buda G¹ and Petrini M¹

Received: April 24, 2020;   Published: May 04, 2020

DOI: 10.32474/LOJPCR.2020.02.000128

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

SARS-COV-2, a novel β-coronavirus, is the cause of a severe inflammatory infectious disease of the respiratory tract (COVID-19). The spread has already taken on pandemic proportions, affecting over 2,5 million people and causing more than 170,000 deaths. The mechanisms and strategies underlying the virus power of penetrating human cells and causing the well-known spectrum of diseases induced by SARS-COV-2 have been explored worldwide. Two host receptors able to specifically inducing virus-host linkage, entry and, consequently, productive infection, have been suggested to interact with the outer membrane spike viral glycoprotein: the angiotensin converting enzyme 2 (ACE2) and the dipeptidyl-peptidase 4 (DPP4), also known as CD26. Both these receptors are highly expressed on several human tissues (i.e. kidney, pancreas, gut, lung, endothelium, pleura, myocardium, connective tissue) accounting for the variable clinical manifestations of COVID-19. CD26 is also over-expressed in stimulated T, B, and NK cells, thus representing an activation marker of the immune system. However, CD26 is not only the functional host receptor for SARSCoV- 2. Indeed, published data available from the previous SARS-CoV and MERS-CoV outbreaks showed that CD26 is also utilized for sustaining inflammation and counteracting the host immune response. Specifically, through CD26, coronavirus may increase inflammatory cytokine production, down- modulate the autophagy, and increase levels of adenosine, hence further deactivating the host immune response. Thus, compounds able to inhibit the DPP4/CD26 pathway might be useful against COVID-19. In this respect, promising therapeutic approaches could include: 1) DPP4 inhibitors, such as sitagliptin, already used for treating diabetic patients; 2) Begelomab, the anti-CD26 monoclonal antibody already successfully employed in the treatment of graft-versus-host disease, and 3) adenosine deaminase agonists, already used in the immunodeficiencies sustained by the adenosine deaminase gene mutations. The article will review some pathogenic landscapes and will hypothesize some promising drugs to face the COVID-19 emergency.

Keywords: COVID-19; SARS, CD26; DPP4; Autophagy; Inflammation; Sitagliptin; Begelomab; Adenosine deaminase

Abstract| Introduction| DPP4/CD26 as Receptor for SARS-Cov-2| DPP4/CD26 as First-Line Player in Inflammation| SARS-Covs, DPP4/CD26 and Autophagy| OUTLOOK: the Employ of DPP4/CD26 Inhibitors Against COVID-19| Conclusion| Acknowledgments| Conflicts of Interest| Authors Contribution| References|